Pasithea Therapeutics Corp.KTTA

Pasithea Therapeutics Corp. reported a net loss of $2.9 million for the quarter ending 31 March 2026, while spending $2.9 million on research and development and posting diluted earnings per share of -$0.12 on 24.3 million diluted shares outstanding. The company’s cash and equivalents stood at $50.4 million at quarter-end, down from an opening balance that the 10-Q does not restate, leaving the exact cash burn for the quarter at $4.8 million under operating activities. Liabilities totalled $1.5 million against $56.4 million of assets, producing shareholder equity of $54.8 million. In other words, the balance sheet is still in the black, but the profit-and-loss column is resolutely in the red.

Pasithea describes itself as a clinical-stage biotechnology company focused on central nervous system disorders and RASopathies, with programmes spanning solid tumours, Neurofibromatosis type 1, ALS, and schizophrenia. Its lead asset, PAS-004, has been accepted for presentation at the European Society for Medical Oncology Congress 2026, an occasion the company will doubtless use to refresh its narrative even as the filing math remains unchanged. The company’s pipeline slide deck and product imagery are polished, but the evidence that matters is the 10-Q and the cash-flow statement, not the marketing collateral.

The quarterly numbers are unambiguous: operating income of -$4.9 million, net income attributable to parent of -$2.9 million, and zero revenue. The board’s latest 13G/A filing on 1 July 2026 notes that ‘no transactions in the securities occurred’, a polite way of saying liquidity is light and ownership changes are more likely to register on an SEC filing than on a trading screen. The company’s cash burn and R&D intensity are fully visible in the 10-Q; the rest is investor relations theatre.

The company’s shareholder base appears to turn over faster than its cash: Schedule 13G filings arrived on 23 June 2026 and again on 1 July 2026, with the earlier 13G/A on 15 May 2026 and a further 4 filing on 22 June 2026. The pace of ownership disclosure suggests either heightened activism or simply the normal churn of small-cap holders, but the consequence is the same: the stock’s float is thin and the filing rhythm is louder than the trading volume.

For now, the market file is a ledger of red ink, steady burn, and thin liquidity, anchored by a $50.4 million cash cushion and a board that is still writing its next move in 13G footnotes rather than in the income statement. The ESMO spotlight in September may change the narrative, but it won’t change the cash-flow math.

What remains unproven is any path to sustained revenue, positive operating income, or a cash-flow profile that doesn’t rely on the next financing or the next clinical readout. Until then, the company’s primary product is the quarterly 10-Q and the secondary product is the Schedule 13G, both of which it delivers on time and without fanfare.